AstraZeneca Acquires Asian Rights To Cubist’s Antibiotic Cubicin
This article was originally published in The Pink Sheet Daily
Executive Summary
Cubist is in talks with potential partners for Japanese rights, which the firm has retained.
You may also be interested in...
Cubist Pharmaceuticals CEO Michael Bonney: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Exec discusses the regulatory climate for anti-infectives and Cubist’s development plans following the successful launch of Cubicin.
Cubist Pharmaceuticals CEO Michael Bonney: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Exec discusses the regulatory climate for anti-infectives and Cubist’s development plans following the successful launch of Cubicin.
Merck Licenses Cubicin For Japan
Deal completes global licensing of the first-in-class lipopeptide antibiotic for Cubist, which could collect over $45 million from Merck subsidiary Banyu.